8 Oct 2021

Futura Medical plc

("Futura" or the "Company")

Board Appointment

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce that Jeff Needham has been appointed to the Board as a non-executive director with immediate effect. 

Jeff brings a wealth of knowledge and experience to the Board having been at Perrigo Company plc, the US-based manufacturer and marketer of consumer healthcare products, for 36 years, and a board director of the Consumer Healthcare Products Association for 12 years. Whilst at Perrigo, Jeff was responsible for the consumer self-care businesses in the Americas, that included Perrigo's US OTC Drug business, Nutritionals, Oral Care and its businesses in Mexico and Canada.  Jeff's focus was on the development and long-term strategic direction of the business, including marketing, sales, new product pipeline development, business development and scientific affairs.

Commenting on the appointment, James Barder, Chief Executive Officer of the Company, said: "We are delighted to welcome Jeff, a seasoned and highly respected industry leader, to the Board of Directors. His unparalleled management, strategic and corporate expertise, especially in Consumer Health, OTC and the USA underscores our ambition and focus on building a global brand to deliver MED3000, our breakthrough treatment for erectile dysfunction to sufferers as a therapy option without the need for a doctor's prescription."

In accordance with Schedule 2(g) of the AIM Rules, Jeffrey Robert Needham (aged 65) holds or has held directorships of the following companies:

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670
 

Nominated Adviser and Sole Broker:
Liberum
Richard Lindley/ Euan Brown/ Kane Collings
Tel: +44 (0) 203 100 2000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 922 0891

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys^® technology. Each DermaSys^® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com